Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21474355 | 0.77 | GRM5 (0.35) | GRM5HCAR2 | |
| SCHEMBL8488909 | 0.74 | GRM5 (0.38) | GRM5HCAR2 | |
| SCHEMBL1476913 | 0.71 | GRM5 (0.40) | GRM5HCAR2 | |
| SCHEMBL29434830 | 0.71 | GRM5 (0.40) | GRM5HCAR2 | |
| SCHEMBL1477711 | 0.71 | GRM5 (0.55) | GRM5 | |
| SCHEMBL18435121 | 0.69 | — | — | |
| SCHEMBL12805238 | 0.69 | — | — | |
| SCHEMBL22163459 | 0.69 | KCNH2 (0.39) | GRM5 | |
| SCHEMBL565871 | 0.69 | — | — | |
| SCHEMBL1040544 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | disclosed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2021028512-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| US-10889610-B2 | Alpha-D-galactoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2021-01-12 | — | — | US | disclosed |
| US-20190315793-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2019-10-17 | — | — | US | disclosed |
| WO-2018011094-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365542-A1 | Selective Agonists of 5-HT2A Receptor and Methods of Use | HTR2A, HTR2C, HTR2B | GRM5 39/4885HCAR2 68/4885 |
| US-20190315793-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS1, LGALS3, LGALS2 | GRM5 1710/4885HCAR2 3015/4885 |
| US-10889610-B2 | Alpha-D-galactoside inhibitors of galectins | LGALS1, LGALS3, LGALS2 | GRM5 1710/4885HCAR2 3015/4885 |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | ARSA, SULT1E1, STS | GRM5 4194/4885HCAR2 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.